JP2015500225A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015500225A5 JP2015500225A5 JP2014543977A JP2014543977A JP2015500225A5 JP 2015500225 A5 JP2015500225 A5 JP 2015500225A5 JP 2014543977 A JP2014543977 A JP 2014543977A JP 2014543977 A JP2014543977 A JP 2014543977A JP 2015500225 A5 JP2015500225 A5 JP 2015500225A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- combination
- treatment
- acceptable salt
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims 11
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 8
- 238000011282 treatment Methods 0.000 claims 8
- JDUBGYFRJFOXQC-KRWDZBQOSA-N 4-amino-n-[(1s)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide Chemical compound C1([C@H](CCO)NC(=O)C2(CCN(CC2)C=2C=3C=CNC=3N=CN=2)N)=CC=C(Cl)C=C1 JDUBGYFRJFOXQC-KRWDZBQOSA-N 0.000 claims 7
- 206010060862 Prostate cancer Diseases 0.000 claims 7
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 7
- 239000002552 dosage form Substances 0.000 claims 6
- 238000011284 combination treatment Methods 0.000 claims 5
- 229960000853 abiraterone Drugs 0.000 claims 4
- GZOSMCIZMLWJML-VJLLXTKPSA-N abiraterone Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CC[C@H](O)CC3=CC2)C)CC[C@@]11C)C=C1C1=CC=CN=C1 GZOSMCIZMLWJML-VJLLXTKPSA-N 0.000 claims 4
- 239000003085 diluting agent Substances 0.000 claims 4
- 229960004671 enzalutamide Drugs 0.000 claims 4
- WXCXUHSOUPDCQV-UHFFFAOYSA-N enzalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C(C)(C)C(=O)N(C=2C=C(C(C#N)=CC=2)C(F)(F)F)C1=S WXCXUHSOUPDCQV-UHFFFAOYSA-N 0.000 claims 4
- 229960004103 abiraterone acetate Drugs 0.000 claims 3
- UVIQSJCZCSLXRZ-UBUQANBQSA-N abiraterone acetate Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CC[C@@H](CC4=CC[C@H]31)OC(=O)C)C=C2C1=CC=CN=C1 UVIQSJCZCSLXRZ-UBUQANBQSA-N 0.000 claims 3
- 102000001307 androgen receptors Human genes 0.000 claims 3
- 108010080146 androgen receptors Proteins 0.000 claims 3
- 230000011664 signaling Effects 0.000 claims 3
- 241000282412 Homo Species 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 claims 1
- JMEYDSHPKCSIJC-UHFFFAOYSA-N 1-[4-[2-[4-[1-[3-(trifluoromethyl)-7,8-dihydro-[1,2,4]triazolo[4,3-b]pyridazin-6-yl]piperidin-4-yl]phenoxy]ethyl]piperazin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCN1CCOC1=CC=C(C2CCN(CC2)C=2CCC=3N(C(=NN=3)C(F)(F)F)N=2)C=C1 JMEYDSHPKCSIJC-UHFFFAOYSA-N 0.000 claims 1
- 229960000997 bicalutamide Drugs 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161564975P | 2011-11-30 | 2011-11-30 | |
| US61/564,975 | 2011-11-30 | ||
| PCT/GB2012/052969 WO2013079964A1 (en) | 2011-11-30 | 2012-11-30 | Combination treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015500225A JP2015500225A (ja) | 2015-01-05 |
| JP2015500225A5 true JP2015500225A5 (enExample) | 2016-01-21 |
| JP6309454B2 JP6309454B2 (ja) | 2018-04-11 |
Family
ID=47295082
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014543977A Active JP6309454B2 (ja) | 2011-11-30 | 2012-11-30 | 癌の併用処置 |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US20140329786A1 (enExample) |
| EP (1) | EP2785349B2 (enExample) |
| JP (1) | JP6309454B2 (enExample) |
| KR (1) | KR102035361B1 (enExample) |
| CN (1) | CN103945849B (enExample) |
| AU (2) | AU2012321110B2 (enExample) |
| CA (1) | CA2856646C (enExample) |
| CY (1) | CY1122624T1 (enExample) |
| DK (1) | DK2785349T4 (enExample) |
| ES (1) | ES2762250T5 (enExample) |
| FI (1) | FI2785349T4 (enExample) |
| HR (1) | HRP20191982T4 (enExample) |
| HU (1) | HUE046667T2 (enExample) |
| IL (1) | IL232530B (enExample) |
| LT (1) | LT2785349T (enExample) |
| MX (1) | MX367640B (enExample) |
| MY (1) | MY175800A (enExample) |
| PH (1) | PH12014500943A1 (enExample) |
| PL (1) | PL2785349T5 (enExample) |
| PT (1) | PT2785349T (enExample) |
| RS (1) | RS59493B2 (enExample) |
| RU (1) | RU2640485C2 (enExample) |
| SG (1) | SG11201401471PA (enExample) |
| SI (1) | SI2785349T2 (enExample) |
| SM (1) | SMT201900708T1 (enExample) |
| WO (1) | WO2013079964A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100047338A1 (en) | 2008-03-14 | 2010-02-25 | Angela Brodie | Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity |
| EP2350096B1 (en) | 2008-10-02 | 2019-12-11 | Salix Pharmaceuticals, Ltd. | Methods of treating hepatic encephalopathy |
| AU2010210422A1 (en) | 2009-02-05 | 2011-08-18 | Tokai Pharmaceuticals, Inc. | Novel prodrugs of steroidal CYP17 inhibitors/antiandrogens |
| HUE037389T2 (hu) | 2010-02-16 | 2018-08-28 | Aragon Pharmaceuticals Inc | Androgén receptor modulátorok és alkalmazásaik |
| AU2012205601B2 (en) | 2011-01-11 | 2016-03-24 | Novartis Ag | Combination |
| US20150005265A1 (en) * | 2011-12-22 | 2015-01-01 | Susan Stewart | Methods and compositions for combination therapy using p13k/mtor inhibitores |
| AU2013204533B2 (en) * | 2012-04-17 | 2017-02-02 | Astrazeneca Ab | Crystalline forms |
| ES2836424T3 (es) | 2012-09-26 | 2021-06-25 | Aragon Pharmaceuticals Inc | Antiandrógenos para tratar el cáncer de próstata no metastásico y resistente a la castración |
| CA3105575A1 (en) | 2013-01-15 | 2014-07-24 | Aragon Pharmaceuticals, Inc. | Androgen receptor modulator and uses thereof |
| KR20150127720A (ko) | 2013-03-14 | 2015-11-17 | 유니버시티 오브 매릴랜드, 발티모어 | 안드로겐 수용체 하향 조절제 및 그의 용도 |
| WO2015023710A1 (en) | 2013-08-12 | 2015-02-19 | Tokai Pharmaceuticals, Inc. | Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies |
| MX2016004267A (es) * | 2013-10-01 | 2016-07-08 | Novartis Ag | Combinacion. |
| US20160235714A1 (en) * | 2013-10-01 | 2016-08-18 | Novartis Ag | Enzalutamide in combination with afuresertib for the treatment of cancer |
| WO2015116696A1 (en) | 2014-01-28 | 2015-08-06 | Massachusetts Institute Of Technology | Combination therapies and methods of use thereof for treating cancer |
| WO2016162229A1 (en) | 2015-04-10 | 2016-10-13 | Capsugel Belgium N.V. | Abiraterone acetate lipid formulations |
| TWI726969B (zh) | 2016-01-11 | 2021-05-11 | 比利時商健生藥品公司 | 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物 |
| US11478453B2 (en) | 2016-07-21 | 2022-10-25 | Hadasit Medical Research Services And Development Ltd. | Treatment for glioblastoma |
| KR20220028178A (ko) * | 2016-12-16 | 2022-03-08 | 강푸 바이오파마슈티칼즈 리미티드 | 조성물, 이의 적용 및 치료 방법 |
| CN107670048B (zh) | 2017-08-30 | 2019-04-26 | 南京明臻医药科技有限公司 | 具有协同抗癌活性的中间体药物和聚乙二醇偶联协同抗癌药物、及其制备方法和应用 |
| JP2020534320A (ja) * | 2017-09-22 | 2020-11-26 | ディスパーソル テクノロジーズ リミテッド ライアビリティ カンパニー | アビラテロン環状オリゴマー薬学的製剤ならびにその形成法および投与法 |
| UA129105C2 (uk) | 2017-10-16 | 2025-01-15 | Арагон Фармасьютикалз, Інк. | Антиандрогени для лікування неметастатичного резистентного до кастрації раку передміхурової залози |
| CN108486041A (zh) * | 2018-03-28 | 2018-09-04 | 华南农业大学 | PI3K/Akt信号通路在鸡胚成纤维细胞内对马立克氏病毒增殖的应用及其检测方法 |
| CN114026106B (zh) | 2019-03-06 | 2025-01-21 | 普洛拉治疗公司 | 阿比特龙前药 |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL297170A (enExample) | 1963-04-04 | 1900-01-01 | ||
| ATE28864T1 (de) | 1982-07-23 | 1987-08-15 | Ici Plc | Amide-derivate. |
| CZ287434B6 (en) | 1992-03-31 | 2000-11-15 | British Tech Group | Use of steroids, substituted in position 17, steroids functioning as carcinostatics and pharmaceutical preparation containing thereof |
| US5439686A (en) | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
| US6749868B1 (en) | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| GB9312853D0 (en) | 1993-06-22 | 1993-08-04 | Euro Celtique Sa | Chemical compounds |
| EP0944388A4 (en) | 1996-04-03 | 2001-08-16 | Merck & Co Inc | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE |
| US6432947B1 (en) | 1997-02-19 | 2002-08-13 | Berlex Laboratories, Inc. | N-heterocyclic derivatives as NOS inhibitors |
| KR100904931B1 (ko) | 1997-06-27 | 2009-06-29 | 아브락시스 바이오사이언스, 엘엘씨 | 나노 입자 및 그의 제조 방법 |
| US6187778B1 (en) | 1997-08-05 | 2001-02-13 | Pfizer Inc. | 4-aminopyrrole (3, 2-D) pyrimidines as neuropeptide Y receptor antagonists |
| US6162804A (en) | 1997-09-26 | 2000-12-19 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| IL139811A0 (en) | 1998-06-04 | 2002-02-10 | Abbott Lab | Cell adhesion-inhibiting antinflammatory compounds |
| PA8474101A1 (es) | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
| US6262066B1 (en) | 1998-07-27 | 2001-07-17 | Schering Corporation | High affinity ligands for nociceptin receptor ORL-1 |
| HK1045306A1 (zh) | 1999-06-03 | 2002-11-22 | Abbott Laboratories | 抑制细胞黏附的抗炎化合物 |
| US7160890B2 (en) | 1999-12-02 | 2007-01-09 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
| PL359563A1 (pl) | 2000-06-26 | 2004-08-23 | Pfizer Products Inc. | Związki pirolo [2,3-d] pirymidynowe jako środki immunosupresyjne |
| ES2251512T3 (es) | 2000-08-31 | 2006-05-01 | F. Hoffmann-La Roche Ag | Derivados de quinazolina como antagonista adrenergicos alfa-1. |
| US6680324B2 (en) | 2000-12-01 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
| EP1347980A4 (en) | 2000-12-01 | 2005-02-09 | Osi Pharm Inc | RECEPTOR SPECIFIC COMPOUNDS OF ADENOSINE-A1, -A2A, AND-A3 AND USES THEREOF |
| US6673802B2 (en) | 2000-12-01 | 2004-01-06 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
| UY27220A1 (es) | 2001-03-23 | 2002-09-30 | Aventis Pharma Sa | Combinación de un taxano con una quinasa ciclina-dependiente |
| NZ555911A (en) | 2002-01-07 | 2008-07-31 | Eisai R&D Man Co Ltd | Deazapurines and uses thereof |
| TW200403058A (en) | 2002-04-19 | 2004-03-01 | Bristol Myers Squibb Co | Heterocyclo inhibitors of potassium channel function |
| RU2321396C2 (ru) | 2002-05-17 | 2008-04-10 | Авентис Фарма С.А. | Применение доцетаксела/доксорубицина/циклофосфамида во вспомогательной терапии рака молочной железы и яичников |
| EP2508204B1 (en) | 2002-06-26 | 2014-09-24 | Ono Pharmaceutical Co., Ltd. | Remedies for diseases caused by vascular contraction or dilation |
| US20040138238A1 (en) | 2002-08-08 | 2004-07-15 | Dhanoa Dale S. | Substituted aminopyrimidine compounds as neurokinin antagonists |
| US20030139427A1 (en) | 2002-08-23 | 2003-07-24 | Osi Pharmaceuticals Inc. | Bicyclic pyrimidinyl derivatives and methods of use thereof |
| WO2004021979A2 (en) | 2002-09-06 | 2004-03-18 | Smithkline Beecham Corporation | PYRROLO[2, 3-d]PYRIMIDINE-4-YL AND PURIN-6-YL UREA COMPOUNDS |
| AU2003290673B2 (en) | 2002-11-08 | 2011-01-06 | Massachusetts Institute Of Technology | Small technetium-99m and rhenium labeled agents and methods for imaging tissues, organs and tumors |
| BR0316991A (pt) | 2002-12-04 | 2005-10-25 | Eisai Co Ltd | Compostos de anel de 1,3-diidro-imidazol fundido |
| US7332525B2 (en) * | 2003-01-17 | 2008-02-19 | Castle Erik P | Method of treatment of prostate cancer and composition for treatment thereof |
| EP1444982A1 (de) | 2003-02-06 | 2004-08-11 | Merckle Gmbh | Verwendung von Purinderivaten als selektive Kinase-Inhibitoren |
| EP1601357A4 (en) | 2003-03-10 | 2007-10-03 | Schering Corp | HETEROCYCLIC KINASE INHIBITORS: METHOD OF USE AND SYNTHESIS |
| US20060128956A1 (en) | 2003-04-21 | 2006-06-15 | Ustav Organicke Chemie A Biochemie Akademie Ved Ceske Republiky | (Purin-6-yl) amino acid and production method thereof |
| FR2856685B1 (fr) | 2003-06-25 | 2005-09-23 | Merck Sante Sas | Derives de thiazolylpiperidine, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent |
| CA2536954C (en) | 2003-08-29 | 2012-11-27 | Exelixis, Inc. | C-kit modulators and methods of use |
| WO2005044181A2 (en) | 2003-09-09 | 2005-05-19 | Temple University-Of The Commonwealth System Of Higher Education | Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors |
| TW200526626A (en) | 2003-09-13 | 2005-08-16 | Astrazeneca Ab | Chemical compounds |
| EP1684694A2 (en) | 2003-11-21 | 2006-08-02 | Array Biopharma, Inc. | Akt protein kinase inhibitors |
| EP2308562B1 (en) | 2003-12-25 | 2015-02-25 | Ono Pharmaceutical Co., Ltd. | Azetidine ring compounds and drugs comprising the same |
| JP5213229B2 (ja) | 2004-04-23 | 2013-06-19 | エグゼリクシス， インコーポレイテッド | キナーゼ調節因子および使用方法 |
| UY29177A1 (es) | 2004-10-25 | 2006-05-31 | Astex Therapeutics Ltd | Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos |
| MY179032A (en) | 2004-10-25 | 2020-10-26 | Cancer Research Tech Ltd | Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors |
| JP5274842B2 (ja) | 2004-12-28 | 2013-08-28 | エグゼリクシス， インコーポレイテッド | 免疫疾患、炎症疾患および増殖疾患の処置のためのセリン−スレオニンキナーゼモジュレーター（ｐ７０Ｓ６Ｋ、Ａｋｔ−１およびＡｋｔ−２）としての［１Ｈ−ピペラゾ［３，４−ｄ］ピリミジン−４−イル］−ピペラジンまたは［１Ｈ−ピペラゾ［３，４−ｄ］ピリミジン−４−イル］−ピペラジン化合物 |
| FR2880540B1 (fr) | 2005-01-13 | 2008-07-11 | Aventis Pharma Sa | Utilisation de derives de la purine comme inhibiteurs de la proteine hsp90 |
| FR2880626B1 (fr) | 2005-01-13 | 2008-04-18 | Aventis Pharma Sa | Derives de la purine, compositions les contenant et utilisation |
| WO2006091450A1 (en) | 2005-02-18 | 2006-08-31 | Lexicon Genetics Incorporated | 4-piperidin-1-yl-7h-pyrrolo[2,3-d]pyrimidine compounds |
| WO2006090129A2 (en) * | 2005-02-23 | 2006-08-31 | Astrazeneca Ab | Bicalutamide for delivering increasing steady state plasma levels |
| EP3106162A1 (en) | 2005-05-13 | 2016-12-21 | The Regents of the University of California | Diarylhydantoin compounds as androgen receptor antagonists for treatment of cancer |
| US20060281768A1 (en) | 2005-06-10 | 2006-12-14 | Gaul Michael D | Thienopyrimidine and thienopyridine kinase modulators |
| KR20080026654A (ko) | 2005-07-14 | 2008-03-25 | 아스텔라스세이야쿠 가부시키가이샤 | 헤테로시클릭 야누스 키나제 3 억제제 |
| WO2007025090A2 (en) | 2005-08-25 | 2007-03-01 | Kalypsys, Inc. | Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase |
| KR101643416B1 (ko) | 2005-08-31 | 2016-07-27 | 아브락시스 바이오사이언스, 엘엘씨 | 증가된 안정성을 가진 수 난용성 약물의 조성물 및 제조방법 |
| CA2880727C (en) | 2005-08-31 | 2019-05-07 | Neil P. Desai | Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents |
| US20070208053A1 (en) | 2006-01-19 | 2007-09-06 | Arnold Lee D | Fused heterobicyclic kinase inhibitors |
| JP2009534454A (ja) | 2006-04-25 | 2009-09-24 | アステックス、セラピューティックス、リミテッド | 医薬化合物 |
| US20090082370A1 (en) | 2006-04-25 | 2009-03-26 | Neil Thomas Thompson | Pharmaceutical Combinations of PK Inhibitors and Other Active Agents |
| WO2007125315A2 (en) | 2006-04-25 | 2007-11-08 | Astex Therapeutics Limited | Pharmaceutical compounds |
| WO2007125321A2 (en) | 2006-04-25 | 2007-11-08 | Astex Therapeutics Limited | Purine and deazapurine derivatives as pharmaceutical compounds |
| EP2029592A1 (en) | 2006-04-25 | 2009-03-04 | Astex Therapeutics Limited | Pharmaceutical compounds |
| AR064416A1 (es) | 2006-12-21 | 2009-04-01 | Cancer Rec Tech Ltd | Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas. |
| US8247421B2 (en) | 2006-12-21 | 2012-08-21 | Vertex Pharmaceuticals Incorporated | 5-cyano-4-(pyrrolo [2,3B] pyridine-3-yl)-pyrimidine derivatives useful as protein kinase inhibitors |
| AR064415A1 (es) | 2006-12-21 | 2009-04-01 | Cancer Rec Tech Ltd | Derivados de pirrolo-piperidinas y purinas,composiciones farmaceuticas que los contienen y usos en trastornos y/o enfermedades mediadas por pka y pkb. |
| AU2008309383B2 (en) * | 2007-10-11 | 2012-04-19 | Astrazeneca Ab | Pyrrolo [2, 3 -D] pyrimidin derivatives as protein kinase B inhibitors |
| AU2010210422A1 (en) * | 2009-02-05 | 2011-08-18 | Tokai Pharmaceuticals, Inc. | Novel prodrugs of steroidal CYP17 inhibitors/antiandrogens |
| EP2396333B1 (en) * | 2009-02-10 | 2013-07-03 | AstraZeneca AB | Triazolo[4,3-b]pyridazine derivatives and their uses for prostate cancer |
| US20120238533A1 (en) * | 2009-09-11 | 2012-09-20 | Bayer Pharma Aktiengesellschaft | (Heteroarylmethyl) Thiohydantoins as anticancer drugs |
| JP6042802B2 (ja) * | 2010-04-27 | 2016-12-14 | ザ・ジョンズ・ホプキンス・ユニバーシティ | 新生物（腫瘍）を治療するための免疫原性組成物及び方法。 |
-
2012
- 2012-11-30 CA CA2856646A patent/CA2856646C/en active Active
- 2012-11-30 HR HRP20191982TT patent/HRP20191982T4/hr unknown
- 2012-11-30 ES ES12795842T patent/ES2762250T5/es active Active
- 2012-11-30 PH PH1/2014/500943A patent/PH12014500943A1/en unknown
- 2012-11-30 SM SM20190708T patent/SMT201900708T1/it unknown
- 2012-11-30 WO PCT/GB2012/052969 patent/WO2013079964A1/en not_active Ceased
- 2012-11-30 DK DK12795842.9T patent/DK2785349T4/da active
- 2012-11-30 RS RS20191392A patent/RS59493B2/sr unknown
- 2012-11-30 KR KR1020147016680A patent/KR102035361B1/ko active Active
- 2012-11-30 PL PL12795842.9T patent/PL2785349T5/pl unknown
- 2012-11-30 US US14/361,718 patent/US20140329786A1/en not_active Abandoned
- 2012-11-30 MX MX2014006547A patent/MX367640B/es active IP Right Grant
- 2012-11-30 SG SG11201401471PA patent/SG11201401471PA/en unknown
- 2012-11-30 HU HUE12795842A patent/HUE046667T2/hu unknown
- 2012-11-30 FI FIEP12795842.9T patent/FI2785349T4/fi active
- 2012-11-30 JP JP2014543977A patent/JP6309454B2/ja active Active
- 2012-11-30 LT LT12795842T patent/LT2785349T/lt unknown
- 2012-11-30 MY MYPI2014701394A patent/MY175800A/en unknown
- 2012-11-30 AU AU2012321110A patent/AU2012321110B2/en active Active
- 2012-11-30 AU AU2013205648A patent/AU2013205648B2/en active Active
- 2012-11-30 EP EP12795842.9A patent/EP2785349B2/en active Active
- 2012-11-30 RU RU2014119713A patent/RU2640485C2/ru active
- 2012-11-30 SI SI201231690T patent/SI2785349T2/sl unknown
- 2012-11-30 PT PT127958429T patent/PT2785349T/pt unknown
- 2012-11-30 CN CN201280059109.1A patent/CN103945849B/zh active Active
-
2014
- 2014-05-08 IL IL232530A patent/IL232530B/en active IP Right Grant
-
2016
- 2016-02-08 US US15/018,157 patent/US9737540B2/en active Active
-
2019
- 2019-12-17 CY CY20191101323T patent/CY1122624T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015500225A5 (enExample) | ||
| RU2014119713A (ru) | Комбинирование лечения рака | |
| WO2015097621A3 (en) | Pharmaceutical combinations | |
| JO3606B1 (ar) | معدل مستقبل الأندروجين في توليفة مع أسيتات أبراتيرون وبريدنيزون لعلاج سرطان البروستاتا | |
| TW201613887A (en) | Antiproliferative compounds and methods of use thereof | |
| JP2016536286A5 (enExample) | ||
| EP3686200A3 (en) | Bicyclic heterocycle compounds and their uses in therapy | |
| WO2015103438A3 (en) | Oncolytic virus adjunct therapy with agents that increase virus infectivity | |
| JP2015502926A5 (enExample) | ||
| WO2014127917A8 (en) | Combination of vaccination and inhibition of the pd-1 pathway | |
| IN2014MN01919A (enExample) | ||
| IL258246B (en) | Isolidine compound, pharmaceutical compositions comprising same, their combinations with therapeutic agents for use in the treatment of cancer | |
| JP2016515628A5 (enExample) | ||
| WO2015095834A3 (en) | Cancer treatments using erk1/2 and bcl-2 family inhibitors | |
| JP2016539157A5 (enExample) | ||
| CA2908957C (en) | Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer | |
| JP2016522202A5 (enExample) | ||
| JP2016532516A5 (enExample) | ||
| WO2015130554A3 (en) | Dosage and administration of anti-igf-1r, anti-erbb3 bispecific antibodies, uses thereof and methods of treatment therewith | |
| HK1251488A1 (zh) | 作为放射致敏剂以及mri和/或x光造影剂的结合纳米粒子的抗核仁素剂 | |
| RU2017141536A (ru) | Замещенные производные индол-5-ола и их терапевтические применения | |
| JP2015507020A5 (enExample) | ||
| JP2016515550A5 (enExample) | ||
| EP3581653A3 (en) | Methods and compositions for treating cancer using peptide nucleic acid-based agents | |
| PH12016502233A1 (en) | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine |